Penn gene therapy spinout exceeds projections with $216M IPO

Penn Medicine spinout Passage Bio raised $216 million through an initial public offering to support the continued development of clinical trials for gene therapies to treat rare central nervous system disorders – exceeding expectations and proving that cell and gene therapies can thrive in the Greater Philadelphia region.

Article from the Philadelphia Business Journal